nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—TACR1—cranial nerve—amyotrophic lateral sclerosis	0.0233	0.116	CbGeAlD
Paroxetine—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.0218	0.109	CbGeAlD
Paroxetine—TACR1—peripheral nervous system—amyotrophic lateral sclerosis	0.0153	0.0765	CbGeAlD
Paroxetine—TACR1—nerve—amyotrophic lateral sclerosis	0.0119	0.0597	CbGeAlD
Paroxetine—SLC6A3—nerve—amyotrophic lateral sclerosis	0.006	0.03	CbGeAlD
Paroxetine—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00568	0.0284	CbGeAlD
Paroxetine—HTR2A—pons—amyotrophic lateral sclerosis	0.00561	0.0281	CbGeAlD
Paroxetine—TACR1—brainstem—amyotrophic lateral sclerosis	0.00513	0.0256	CbGeAlD
Paroxetine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00484	0.0242	CbGeAlD
Paroxetine—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00479	0.0239	CbGeAlD
Paroxetine—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.0045	0.0225	CbGeAlD
Paroxetine—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00613	CcSEcCtD
Paroxetine—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00613	CcSEcCtD
Paroxetine—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00596	CcSEcCtD
Paroxetine—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00596	CcSEcCtD
Paroxetine—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00596	CcSEcCtD
Paroxetine—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00418	0.00587	CcSEcCtD
Paroxetine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00412	0.0206	CbGeAlD
Paroxetine—HTR2A—appendage—amyotrophic lateral sclerosis	0.00411	0.0205	CbGeAlD
Paroxetine—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00407	0.00572	CcSEcCtD
Paroxetine—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00407	0.00572	CcSEcCtD
Paroxetine—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00391	0.0055	CcSEcCtD
Paroxetine—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00543	CcSEcCtD
Paroxetine—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00543	CcSEcCtD
Paroxetine—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00536	CcSEcCtD
Paroxetine—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00536	CcSEcCtD
Paroxetine—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00536	CcSEcCtD
Paroxetine—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00377	0.0053	CcSEcCtD
Paroxetine—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00377	0.0053	CcSEcCtD
Paroxetine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00377	0.0053	CcSEcCtD
Paroxetine—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00374	0.0187	CbGeAlD
Paroxetine—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00368	0.00517	CcSEcCtD
Paroxetine—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00364	0.00511	CcSEcCtD
Paroxetine—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00505	CcSEcCtD
Paroxetine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00355	0.005	CcSEcCtD
Paroxetine—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00494	CcSEcCtD
Paroxetine—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00489	CcSEcCtD
Paroxetine—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00478	CcSEcCtD
Paroxetine—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00463	CcSEcCtD
Paroxetine—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00459	CcSEcCtD
Paroxetine—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00459	CcSEcCtD
Paroxetine—TACR1—spinal cord—amyotrophic lateral sclerosis	0.00319	0.0159	CbGeAlD
Paroxetine—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00445	CcSEcCtD
Paroxetine—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00441	CcSEcCtD
Paroxetine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00441	CcSEcCtD
Paroxetine—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00441	CcSEcCtD
Paroxetine—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00437	CcSEcCtD
Paroxetine—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00433	CcSEcCtD
Paroxetine—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00433	CcSEcCtD
Paroxetine—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00429	CcSEcCtD
Paroxetine—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00425	CcSEcCtD
Paroxetine—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00425	CcSEcCtD
Paroxetine—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00302	0.00425	CcSEcCtD
Paroxetine—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00299	0.00421	CcSEcCtD
Paroxetine—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00297	0.00417	CcSEcCtD
Paroxetine—Mania—Riluzole—amyotrophic lateral sclerosis	0.00294	0.00413	CcSEcCtD
Paroxetine—HTR2A—nerve—amyotrophic lateral sclerosis	0.00291	0.0146	CbGeAlD
Paroxetine—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00289	0.00406	CcSEcCtD
Paroxetine—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00403	CcSEcCtD
Paroxetine—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00403	CcSEcCtD
Paroxetine—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00399	CcSEcCtD
Paroxetine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00399	CcSEcCtD
Paroxetine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00392	CcSEcCtD
Paroxetine—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00389	CcSEcCtD
Paroxetine—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00386	CcSEcCtD
Paroxetine—Abscess—Riluzole—amyotrophic lateral sclerosis	0.0027	0.0038	CcSEcCtD
Paroxetine—TACR1—nervous system—amyotrophic lateral sclerosis	0.00269	0.0134	CbGeAlD
Paroxetine—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00374	CcSEcCtD
Paroxetine—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00374	CcSEcCtD
Paroxetine—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00264	0.00371	CcSEcCtD
Paroxetine—TACR1—central nervous system—amyotrophic lateral sclerosis	0.00259	0.0129	CbGeAlD
Paroxetine—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00363	CcSEcCtD
Paroxetine—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00258	0.0129	CbGeAlD
Paroxetine—CHRM4—nervous system—amyotrophic lateral sclerosis	0.00252	0.0126	CbGeAlD
Paroxetine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00349	CcSEcCtD
Paroxetine—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00344	CcSEcCtD
Paroxetine—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00342	CcSEcCtD
Paroxetine—CHRM4—central nervous system—amyotrophic lateral sclerosis	0.00243	0.0121	CbGeAlD
Paroxetine—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00335	CcSEcCtD
Paroxetine—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00333	CcSEcCtD
Paroxetine—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00333	CcSEcCtD
Paroxetine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00236	0.0118	CbGeAlD
Paroxetine—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00331	CcSEcCtD
Paroxetine—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00331	CcSEcCtD
Paroxetine—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00328	CcSEcCtD
Paroxetine—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00328	CcSEcCtD
Paroxetine—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00326	CcSEcCtD
Paroxetine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00324	CcSEcCtD
Paroxetine—Gout—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00322	CcSEcCtD
Paroxetine—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00227	0.0032	CcSEcCtD
Paroxetine—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00318	CcSEcCtD
Paroxetine—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00318	CcSEcCtD
Paroxetine—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00318	CcSEcCtD
Paroxetine—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00316	CcSEcCtD
Paroxetine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00308	CcSEcCtD
Paroxetine—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.00218	0.0109	CbGeAlD
Paroxetine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00306	CcSEcCtD
Paroxetine—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00304	CcSEcCtD
Paroxetine—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00301	CcSEcCtD
Paroxetine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00301	CcSEcCtD
Paroxetine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00301	CcSEcCtD
Paroxetine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00301	CcSEcCtD
Paroxetine—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00297	CcSEcCtD
Paroxetine—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00297	CcSEcCtD
Paroxetine—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00294	CcSEcCtD
Paroxetine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00208	0.0104	CbGeAlD
Paroxetine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0029	CcSEcCtD
Paroxetine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0029	CcSEcCtD
Paroxetine—TACR1—brain—amyotrophic lateral sclerosis	0.00205	0.0103	CbGeAlD
Paroxetine—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00287	CcSEcCtD
Paroxetine—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00285	CcSEcCtD
Paroxetine—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00282	CcSEcCtD
Paroxetine—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00282	CcSEcCtD
Paroxetine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00199	0.00993	CbGeAlD
Paroxetine—CHRM5—nervous system—amyotrophic lateral sclerosis	0.00197	0.00986	CbGeAlD
Paroxetine—Coma—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00275	CcSEcCtD
Paroxetine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00272	CcSEcCtD
Paroxetine—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00272	CcSEcCtD
Paroxetine—CHRM4—brain—amyotrophic lateral sclerosis	0.00193	0.00965	CbGeAlD
Paroxetine—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00268	CcSEcCtD
Paroxetine—CHRM5—central nervous system—amyotrophic lateral sclerosis	0.0019	0.0095	CbGeAlD
Paroxetine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00263	CcSEcCtD
Paroxetine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00261	CcSEcCtD
Paroxetine—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00261	CcSEcCtD
Paroxetine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00258	CcSEcCtD
Paroxetine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00256	CcSEcCtD
Paroxetine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00256	CcSEcCtD
Paroxetine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00253	CcSEcCtD
Paroxetine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00251	CcSEcCtD
Paroxetine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00251	CcSEcCtD
Paroxetine—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00178	0.0025	CcSEcCtD
Paroxetine—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00248	CcSEcCtD
Paroxetine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00244	CcSEcCtD
Paroxetine—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00244	CcSEcCtD
Paroxetine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00243	CcSEcCtD
Paroxetine—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00241	CcSEcCtD
Paroxetine—Injury—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00237	CcSEcCtD
Paroxetine—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00235	CcSEcCtD
Paroxetine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00232	CcSEcCtD
Paroxetine—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00232	CcSEcCtD
Paroxetine—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00231	CcSEcCtD
Paroxetine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0023	CcSEcCtD
Paroxetine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00229	CcSEcCtD
Paroxetine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00226	CcSEcCtD
Paroxetine—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00225	CcSEcCtD
Paroxetine—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.0016	0.00801	CbGeAlD
Paroxetine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00224	CcSEcCtD
Paroxetine—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00219	CcSEcCtD
Paroxetine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00218	CcSEcCtD
Paroxetine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00218	CcSEcCtD
Paroxetine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00218	CcSEcCtD
Paroxetine—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00216	CcSEcCtD
Paroxetine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00215	CcSEcCtD
Paroxetine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00215	CcSEcCtD
Paroxetine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00213	CcSEcCtD
Paroxetine—CHRM5—brain—amyotrophic lateral sclerosis	0.00151	0.00754	CbGeAlD
Paroxetine—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00211	CcSEcCtD
Paroxetine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00207	CcSEcCtD
Paroxetine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00207	CcSEcCtD
Paroxetine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00147	0.00734	CbGeAlD
Paroxetine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00205	CcSEcCtD
Paroxetine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00145	0.00725	CbGeAlD
Paroxetine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00203	CcSEcCtD
Paroxetine—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00201	CcSEcCtD
Paroxetine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00199	CcSEcCtD
Paroxetine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00199	CcSEcCtD
Paroxetine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00197	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00196	CcSEcCtD
Paroxetine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00193	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00192	CcSEcCtD
Paroxetine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00192	CcSEcCtD
Paroxetine—HTR2A—embryo—amyotrophic lateral sclerosis	0.00136	0.00682	CbGeAlD
Paroxetine—CHRM2—nervous system—amyotrophic lateral sclerosis	0.00135	0.00677	CbGeAlD
Paroxetine—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00135	0.00675	CbGeAlD
Paroxetine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00189	CcSEcCtD
Paroxetine—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00189	CcSEcCtD
Paroxetine—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00189	CcSEcCtD
Paroxetine—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00185	CcSEcCtD
Paroxetine—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00184	CcSEcCtD
Paroxetine—CHRM2—central nervous system—amyotrophic lateral sclerosis	0.0013	0.00652	CbGeAlD
Paroxetine—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.0013	0.0065	CbGeAlD
Paroxetine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00181	CcSEcCtD
Paroxetine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00179	CcSEcCtD
Paroxetine—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00127	0.00635	CbGeAlD
Paroxetine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00176	CcSEcCtD
Paroxetine—HTR2A—brainstem—amyotrophic lateral sclerosis	0.00125	0.00625	CbGeAlD
Paroxetine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00174	CcSEcCtD
Paroxetine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00124	0.00619	CbGeAlD
Paroxetine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00174	CcSEcCtD
Paroxetine—CHRM1—nervous system—amyotrophic lateral sclerosis	0.00123	0.00616	CbGeAlD
Paroxetine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00172	CcSEcCtD
Paroxetine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00172	CcSEcCtD
Paroxetine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00171	CcSEcCtD
Paroxetine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00169	CcSEcCtD
Paroxetine—Depression—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00168	CcSEcCtD
Paroxetine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.00119	0.00596	CbGeAlD
Paroxetine—CHRM1—central nervous system—amyotrophic lateral sclerosis	0.00119	0.00593	CbGeAlD
Paroxetine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00166	CcSEcCtD
Paroxetine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00165	CcSEcCtD
Paroxetine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00165	CcSEcCtD
Paroxetine—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00164	CcSEcCtD
Paroxetine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00164	CcSEcCtD
Paroxetine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00163	CcSEcCtD
Paroxetine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00161	CcSEcCtD
Paroxetine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0016	CcSEcCtD
Paroxetine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00114	0.00569	CbGeAlD
Paroxetine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00159	CcSEcCtD
Paroxetine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00159	CcSEcCtD
Paroxetine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00158	CcSEcCtD
Paroxetine—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00157	CcSEcCtD
Paroxetine—CHRM3—nervous system—amyotrophic lateral sclerosis	0.0011	0.00551	CbGeAlD
Paroxetine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00154	CcSEcCtD
Paroxetine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00109	0.00545	CbGeAlD
Paroxetine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00152	CcSEcCtD
Paroxetine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00151	CcSEcCtD
Paroxetine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00151	CcSEcCtD
Paroxetine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00151	CcSEcCtD
Paroxetine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0015	CcSEcCtD
Paroxetine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0015	CcSEcCtD
Paroxetine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0015	CcSEcCtD
Paroxetine—CHRM3—central nervous system—amyotrophic lateral sclerosis	0.00106	0.00531	CbGeAlD
Paroxetine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00149	CcSEcCtD
Paroxetine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00148	CcSEcCtD
Paroxetine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00105	0.00524	CbGeAlD
Paroxetine—CHRM2—brain—amyotrophic lateral sclerosis	0.00104	0.00517	CbGeAlD
Paroxetine—SLC6A3—brain—amyotrophic lateral sclerosis	0.00103	0.00516	CbGeAlD
Paroxetine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00143	CcSEcCtD
Paroxetine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.001	0.00141	CcSEcCtD
Paroxetine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000996	0.0014	CcSEcCtD
Paroxetine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00137	CcSEcCtD
Paroxetine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00097	0.00136	CcSEcCtD
Paroxetine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000968	0.00136	CcSEcCtD
Paroxetine—Chills—Riluzole—amyotrophic lateral sclerosis	0.000963	0.00135	CcSEcCtD
Paroxetine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00135	CcSEcCtD
Paroxetine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000949	0.00133	CcSEcCtD
Paroxetine—SLC6A4—brain—amyotrophic lateral sclerosis	0.000946	0.00473	CbGeAlD
Paroxetine—CHRM1—brain—amyotrophic lateral sclerosis	0.000942	0.00471	CbGeAlD
Paroxetine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000941	0.00132	CcSEcCtD
Paroxetine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000935	0.00131	CcSEcCtD
Paroxetine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000921	0.00129	CcSEcCtD
Paroxetine—Tension—Riluzole—amyotrophic lateral sclerosis	0.000917	0.00129	CcSEcCtD
Paroxetine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000915	0.00129	CcSEcCtD
Paroxetine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000908	0.00128	CcSEcCtD
Paroxetine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000904	0.00127	CcSEcCtD
Paroxetine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000899	0.00126	CcSEcCtD
Paroxetine—ABCB1—embryo—amyotrophic lateral sclerosis	0.000894	0.00447	CbGeAlD
Paroxetine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00123	CcSEcCtD
Paroxetine—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000872	0.00436	CbGeAlD
Paroxetine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00122	CcSEcCtD
Paroxetine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000864	0.00121	CcSEcCtD
Paroxetine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000859	0.00121	CcSEcCtD
Paroxetine—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000854	0.0012	CcSEcCtD
Paroxetine—CHRM3—brain—amyotrophic lateral sclerosis	0.000843	0.00422	CbGeAlD
Paroxetine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000843	0.00118	CcSEcCtD
Paroxetine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00084	0.00118	CcSEcCtD
Paroxetine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000838	0.00118	CcSEcCtD
Paroxetine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000837	0.00118	CcSEcCtD
Paroxetine—SLC6A2—brain—amyotrophic lateral sclerosis	0.000833	0.00416	CbGeAlD
Paroxetine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000826	0.00116	CcSEcCtD
Paroxetine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000821	0.00115	CcSEcCtD
Paroxetine—Cough—Riluzole—amyotrophic lateral sclerosis	0.000816	0.00115	CcSEcCtD
Paroxetine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00081	0.00114	CcSEcCtD
Paroxetine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000807	0.00113	CcSEcCtD
Paroxetine—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000803	0.00401	CbGeAlD
Paroxetine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000796	0.00112	CcSEcCtD
Paroxetine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000796	0.00112	CcSEcCtD
Paroxetine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000796	0.00112	CcSEcCtD
Paroxetine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000793	0.00111	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00111	CcSEcCtD
Paroxetine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00111	CcSEcCtD
Paroxetine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000778	0.00109	CcSEcCtD
Paroxetine—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.000777	0.00388	CbGeAlD
Paroxetine—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000773	0.00386	CbGeAlD
Paroxetine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000769	0.00108	CcSEcCtD
Paroxetine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00107	CcSEcCtD
Paroxetine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00107	CcSEcCtD
Paroxetine—Infection—Riluzole—amyotrophic lateral sclerosis	0.000758	0.00107	CcSEcCtD
Paroxetine—Shock—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00106	CcSEcCtD
Paroxetine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000748	0.00105	CcSEcCtD
Paroxetine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000747	0.00105	CcSEcCtD
Paroxetine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000744	0.00105	CcSEcCtD
Paroxetine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00104	CcSEcCtD
Paroxetine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000737	0.00104	CcSEcCtD
Paroxetine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000713	0.001	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000695	0.000977	CcSEcCtD
Paroxetine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00069	0.00097	CcSEcCtD
Paroxetine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000685	0.000963	CcSEcCtD
Paroxetine—CYP2C8—brain—amyotrophic lateral sclerosis	0.000684	0.00342	CbGeAlD
Paroxetine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00068	0.000956	CcSEcCtD
Paroxetine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000678	0.000953	CcSEcCtD
Paroxetine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000671	0.000944	CcSEcCtD
Paroxetine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000663	0.000932	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000659	0.000926	CcSEcCtD
Paroxetine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000658	0.000925	CcSEcCtD
Paroxetine—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000655	0.00327	CbGeAlD
Paroxetine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000652	0.000917	CcSEcCtD
Paroxetine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000652	0.000917	CcSEcCtD
Paroxetine—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000631	0.00315	CbGeAlD
Paroxetine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000629	0.000884	CcSEcCtD
Paroxetine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000624	0.000877	CcSEcCtD
Paroxetine—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000616	0.00308	CbGeAlD
Paroxetine—CYP2B6—brain—amyotrophic lateral sclerosis	0.000614	0.00307	CbGeAlD
Paroxetine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000606	0.000852	CcSEcCtD
Paroxetine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000603	0.000848	CcSEcCtD
Paroxetine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000603	0.000848	CcSEcCtD
Paroxetine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000597	0.00298	CbGeAlD
Paroxetine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000574	0.00287	CbGeAlD
Paroxetine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000571	0.00285	CbGeAlD
Paroxetine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000562	0.00079	CcSEcCtD
Paroxetine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000561	0.00281	CbGeAlD
Paroxetine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000547	0.000769	CcSEcCtD
Paroxetine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00054	0.000759	CcSEcCtD
Paroxetine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000522	0.000734	CcSEcCtD
Paroxetine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000509	0.00255	CbGeAlD
Paroxetine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000504	0.000709	CcSEcCtD
Paroxetine—HTR2A—brain—amyotrophic lateral sclerosis	0.000501	0.0025	CbGeAlD
Paroxetine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000485	0.000682	CcSEcCtD
Paroxetine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000481	0.000676	CcSEcCtD
Paroxetine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000481	0.000676	CcSEcCtD
Paroxetine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000478	0.000672	CcSEcCtD
Paroxetine—CYP2D6—brain—amyotrophic lateral sclerosis	0.000456	0.00228	CbGeAlD
Paroxetine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000453	0.000637	CcSEcCtD
Paroxetine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000429	0.00215	CbGeAlD
Paroxetine—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000413	0.00207	CbGeAlD
Paroxetine—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000404	0.00202	CbGeAlD
Paroxetine—ABCB1—brain—amyotrophic lateral sclerosis	0.000328	0.00164	CbGeAlD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.01e-05	0.000904	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	8e-05	0.000903	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	8e-05	0.000903	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	7.99e-05	0.000901	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.96e-05	0.000899	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—DAO—amyotrophic lateral sclerosis	7.94e-05	0.000896	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—C3—amyotrophic lateral sclerosis	7.82e-05	0.000883	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	7.69e-05	0.000867	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.59e-05	0.000856	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	7.56e-05	0.000852	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	7.52e-05	0.000848	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.49e-05	0.000845	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.46e-05	0.000842	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	7.38e-05	0.000833	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	7.32e-05	0.000826	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.27e-05	0.000821	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	7.27e-05	0.00082	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.23e-05	0.000816	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.21e-05	0.000814	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.17e-05	0.000809	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.17e-05	0.000809	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.14e-05	0.000806	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.13e-05	0.000805	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.11e-05	0.000802	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.04e-05	0.000794	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.04e-05	0.000794	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.97e-05	0.000786	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.97e-05	0.000786	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	6.92e-05	0.00078	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	6.83e-05	0.000771	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.8e-05	0.000768	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	6.74e-05	0.000761	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.67e-05	0.000753	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	6.57e-05	0.000741	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	6.57e-05	0.000741	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	6.54e-05	0.000738	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.51e-05	0.000735	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	6.51e-05	0.000735	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	6.51e-05	0.000735	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.49e-05	0.000733	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.48e-05	0.000731	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.46e-05	0.000729	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.46e-05	0.000729	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	6.4e-05	0.000722	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.39e-05	0.000721	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.39e-05	0.000721	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	6.38e-05	0.00072	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.38e-05	0.000719	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	6.26e-05	0.000707	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.19e-05	0.000698	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	6.18e-05	0.000697	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	6.18e-05	0.000697	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.1e-05	0.000689	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.07e-05	0.000685	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PLB1—amyotrophic lateral sclerosis	6.02e-05	0.000679	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	6.01e-05	0.000678	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	5.96e-05	0.000672	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.93e-05	0.000669	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	5.78e-05	0.000653	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.74e-05	0.000648	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.67e-05	0.00064	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.59e-05	0.00063	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.57e-05	0.000629	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSR—amyotrophic lateral sclerosis	5.55e-05	0.000627	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.54e-05	0.000625	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.54e-05	0.000625	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.51e-05	0.000622	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.51e-05	0.000621	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	5.5e-05	0.00062	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.49e-05	0.00062	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.44e-05	0.000614	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.43e-05	0.000613	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.39e-05	0.000609	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	5.25e-05	0.000592	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	5.23e-05	0.00059	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	5.21e-05	0.000587	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.18e-05	0.000584	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.08e-05	0.000573	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.05e-05	0.00057	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	5.04e-05	0.000569	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.03e-05	0.000568	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.02e-05	0.000567	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.98e-05	0.000562	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	4.78e-05	0.000539	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.77e-05	0.000539	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	4.75e-05	0.000536	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.75e-05	0.000536	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.74e-05	0.000535	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.73e-05	0.000534	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	4.71e-05	0.000531	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.69e-05	0.000529	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.62e-05	0.000521	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CHAT—amyotrophic lateral sclerosis	4.56e-05	0.000515	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.54e-05	0.000513	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.52e-05	0.000511	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.5e-05	0.000508	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.49e-05	0.000506	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.44e-05	0.000501	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.42e-05	0.000499	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	4.38e-05	0.000495	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.38e-05	0.000494	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.36e-05	0.000492	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.34e-05	0.00049	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	4.33e-05	0.000489	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.3e-05	0.000485	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.19e-05	0.000473	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.15e-05	0.000468	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	4.05e-05	0.000456	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	4.02e-05	0.000454	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.02e-05	0.000453	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	3.92e-05	0.000443	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	3.91e-05	0.000442	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.9e-05	0.00044	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.89e-05	0.000439	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.87e-05	0.000437	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.86e-05	0.000435	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.85e-05	0.000434	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.83e-05	0.000432	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.82e-05	0.000431	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.82e-05	0.000431	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.81e-05	0.00043	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.78e-05	0.000426	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.73e-05	0.000421	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.68e-05	0.000416	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.66e-05	0.000413	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	3.6e-05	0.000406	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	3.57e-05	0.000403	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	3.52e-05	0.000398	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.5e-05	0.000395	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.48e-05	0.000393	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.41e-05	0.000385	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.34e-05	0.000376	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	3.32e-05	0.000375	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	3.32e-05	0.000375	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	3.29e-05	0.000372	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.22e-05	0.000363	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.2e-05	0.000361	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.19e-05	0.00036	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.19e-05	0.00036	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.16e-05	0.000356	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.13e-05	0.000353	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.11e-05	0.000351	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.1e-05	0.00035	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.07e-05	0.000347	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.03e-05	0.000342	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.02e-05	0.000341	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3e-05	0.000338	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.98e-05	0.000336	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.89e-05	0.000327	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.85e-05	0.000322	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.84e-05	0.000321	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.83e-05	0.000319	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.82e-05	0.000318	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.8e-05	0.000316	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.79e-05	0.000315	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.73e-05	0.000308	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.71e-05	0.000306	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	2.7e-05	0.000305	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.68e-05	0.000303	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.64e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.63e-05	0.000297	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.62e-05	0.000296	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.6e-05	0.000293	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.58e-05	0.000291	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.48e-05	0.00028	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.48e-05	0.000279	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.47e-05	0.000278	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.47e-05	0.000278	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.46e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.45e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.43e-05	0.000275	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.37e-05	0.000268	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.36e-05	0.000266	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.35e-05	0.000265	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.34e-05	0.000264	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.32e-05	0.000262	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.31e-05	0.00026	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.25e-05	0.000254	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.21e-05	0.000249	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.11e-05	0.000238	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.08e-05	0.000234	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.05e-05	0.000231	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.02e-05	0.000228	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.01e-05	0.000227	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2e-05	0.000226	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.98e-05	0.000224	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.94e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.91e-05	0.000215	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.9e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.89e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.88e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.87e-05	0.00021	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—amyotrophic lateral sclerosis	1.85e-05	0.000209	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.82e-05	0.000206	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.79e-05	0.000201	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.69e-05	0.000191	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.68e-05	0.000189	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.67e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.66e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.65e-05	0.000186	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.64e-05	0.000185	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	1.59e-05	0.00018	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.56e-05	0.000176	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.56e-05	0.000176	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.55e-05	0.000175	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.55e-05	0.000175	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.53e-05	0.000173	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.47e-05	0.000165	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.47e-05	0.000165	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.45e-05	0.000164	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.43e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.4e-05	0.000158	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.39e-05	0.000156	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	1.35e-05	0.000152	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.35e-05	0.000152	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.34e-05	0.000151	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.33e-05	0.00015	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.29e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.28e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.28e-05	0.000145	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.27e-05	0.000143	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.27e-05	0.000143	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.24e-05	0.00014	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.19e-05	0.000134	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.18e-05	0.000133	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.11e-05	0.000125	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.1e-05	0.000124	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.09e-05	0.000123	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.94e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.89e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.86e-06	0.000111	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.76e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.4e-06	0.000106	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.4e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.35e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.32e-06	0.000105	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.25e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.23e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.01e-06	0.000102	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.44e-06	9.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.39e-06	9.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.37e-06	9.44e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.28e-06	9.35e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.06e-06	9.09e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.59e-06	8.57e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.53e-06	8.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.38e-06	7.19e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.34e-06	7.15e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.32e-06	7.13e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.26e-06	7.06e-05	CbGpPWpGaD
